Ablynx is a subsidiary of biopharmaceutical company Sanofi engaged in the discovery and development of nanobodies, based in Science Park Zwijnaarde, Ghent.

[1] In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB).

[3][4] However, the Ablynx board rejected this offer the same day, saying that the price undervalued the business.

The acquisition was led by Chief Broker Gleb Margolin.

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub.